OneSource Q2 FY27 Profit Rises as Margin Reaches 31.6%

Q2 results show stronger operating performance

OneSource Specialty Pharma reported a sharp improvement in profitability for the quarter ended September 30, 2026. The company’s standalone net profit was stated at ₹86.2 crore in Q2 FY27, compared with ₹37.1 crore in the corresponding quarter a year earlier. The improvement came as the specialty contract development and manufacturing organisation, or CDMO, continued to scale its manufacturing platform. Separately reported Q2 operating figures showed revenue of ₹516.2 crore, up 37.4% year-on-year from ₹376 crore. EBITDA rose 53% year-on-year to ₹163.2 crore from ₹107 crore. The EBITDA margin increased to 31.6% from 28.4%, an expansion of more than 300 basis points. OneSource shares rose as much as 8% on October 27 following the quarterly results.

Reported profit figures need to be read separately

The available Q2 information includes more than one profit measure. The standalone result was reported as a net profit of ₹86.2 crore, versus ₹37.1 crore a year earlier. Another results summary cited net profit of ₹57.4 crore for the quarter, compared with ₹10.4 crore in the year-ago period. The supplied information does not specify the accounting basis or reconciliation between these two profit figures. Investors should therefore distinguish the standalone profit data from the separately cited quarterly net-profit figure. The common operational indicators in the reported update are revenue growth, EBITDA growth and margin expansion. The company scheduled its Q2 FY27 earnings call for October 27, 2026, which provides the relevant forum for management commentary on the reported numbers.

Revenue and EBITDA growth supported margins

Revenue growth was a central feature of the September-quarter update. Quarterly revenue reached ₹516.2 crore, up 37.4% from ₹376 crore in the comparable period. EBITDA increased faster than revenue, rising to ₹163.2 crore from ₹107 crore. This lifted the EBITDA margin by 320 basis points to 31.6%. The margin movement indicates that profitability improved alongside sales growth during the quarter. The reported performance was compared with a lower base in the prior-year quarter. Still, the combination of revenue expansion and higher operating margin was the principal reason cited for the market’s positive response.

Semaglutide launches remain an operating driver

OneSource attributed its recent operating momentum to commercial launches of semaglutide in Canada and India, alongside new customer contracts. The company is described as the only CDMO with generic semaglutide approvals across G7 countries. It currently supplies semaglutide and liraglutide to India, Canada and Saudi Arabia. Partner Hikma launched semaglutide in Saudi Arabia during Q2 FY27. In India, OneSource manufactures 10 of the 28 semaglutide pens sold, according to the supplied information. These commercial supply arrangements are relevant because they support utilisation of the company’s specialty manufacturing network. They also form part of the company’s broader focus on complex injectables and drug-device combinations.

Earlier Q1 results set the growth base

The September-quarter performance followed a stronger first quarter. OneSource reported Q1 FY27 revenue of ₹449 crore, up 37.3% year-on-year from ₹327 crore. Q1 EBITDA was ₹123.3 crore, a 39% increase year-on-year, while the EBITDA margin stood at 27.5%. Net profit for the June 2026 quarter was reported at ₹25 crore. The company had posted a full-year FY26 loss of ₹74 crore. The move from the FY26 loss to profits in the first two reported FY27 quarters is an important part of the current earnings narrative. However, quarterly results should be assessed in the context of capacity additions and the timing of commercial launches.

Capacity expansion is under way

The company is expanding its lyophilisation injectable platform in India. Its stated plan is to double vial capacity and triple lyophilisation capacity. OneSource is also adding drug-device combination, or DDC, capacity. Management had said that a second DDC cartridge line would commercialise in the current quarter, doubling sterile days, while another line was planned within FY27. Three DDC lines are expected to be fully available for FY28, with a fourth line planned later in that year. Management expects the new DDC capacity to support a revenue ramp in the second half of FY27. The expansion is intended to meet demand from customers requiring complex injectable and device-drug manufacturing capabilities.

Shutdown could affect reported numbers temporarily

The capacity programme also carries a near-term operational consideration. OneSource disclosed a four-month shutdown from Q2 FY27 to Q3 FY27 for installation of a high-viscosity line. The company said this could temporarily affect reported numbers. Such shutdowns can influence production volumes and the timing of revenue recognition while equipment is installed and qualified. The reported Q2 performance therefore needs to be viewed alongside this planned interruption. The company has not provided a quantified impact from the shutdown in the supplied information. Its stated objective remains to build additional manufacturing capability for future commercial demand.

Management retains FY28 targets

Management reiterated its FY28 organic target of US$400 million in revenue and a 40% EBITDA margin. A separate management disclosure described the same objective as US$400 million of organic revenue and US$160 million of EBITDA. The target remains dependent on commercial execution, capacity availability and customer launches. Broker estimates cited in the supplied material place FY27 revenue at ₹2,354.5 crore and EBITDA at ₹941.8 crore. For FY28, the estimates are ₹3,761.6 crore of revenue and ₹1,553.5 crore of EBITDA. These are external estimates and not company guidance. The company’s own guidance is denominated in US dollars and should not be directly compared with rupee estimates without an exchange-rate assumption.

Why the quarter matters for investors

The Q2 update points to rising operating leverage in OneSource’s specialty CDMO platform. Revenue increased by more than 37%, while EBITDA increased by 53%, allowing the operating margin to improve. The company’s semaglutide business, DDC customer base and injectable capacity additions are key operating areas disclosed in the update. The Indian specialty pharmaceutical CDMO sector is also benefiting from global outsourcing demand for complex injectables and device-drug combinations. For OneSource, the near-term focus will be commercial execution, the planned high-viscosity line installation and the pace at which new DDC capacity becomes available. Management’s Q2 earnings call and subsequent disclosures will provide further detail on these milestones.

Outlook remains tied to execution

OneSource Specialty Pharma’s Q2 FY27 update showed higher profit, revenue and EBITDA margin compared with the prior-year period. The company retained its FY28 organic revenue and margin objectives while continuing to invest in injectable and DDC capacity. The planned shutdown may affect reported figures temporarily, but it is linked to the expansion of the manufacturing platform. Investors will watch management’s commentary on semaglutide supply, new customer contracts, capacity commissioning and the timing of second-half FY27 growth.